A Peek at the PEC: An Overview of Formulary Management at the Department of Defense (DoD) TRICARE Management Activity (TMA) Pharmacoeconomic Center (PEC) LCDR Marisol Martinez, PharmD Fort Sam Houston, TX DoD/TMA Pharmacoeconomic Center Promoting high quality, cost effective drug therapy throughout the Military Health System www.pec.ha.osd.mil Objectives • Discuss the Department of Defense (DoD) TRICARE pharmacy benefit and the role and responsibility of the PEC in formulary management • Discuss the lessons learned from the DoD P&T process for conducting drug class reviews to determine clinical and cost effectiveness • Review the functions of the Pharmacoeconomic Outcomes Research Team (PORT) and the implications of formulary decisions on military treatment facilities (MTF) DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 2 Outline • • • • • • • • • TRICARE Pharmacy Benefit Roles of the PEC Process Timeline Determining Clinical Effectiveness Determining Cost Effectiveness Functions of the PORT Implications of P&T’s decisions Conclusion Questions DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 3 TRICARE Pharmacy Benefit Background • Points of service – – – • Population – 9.7 million beneficiaries – • • MTF Retail Mail Order Active duty, retired Uniformed Service members, and family members Expenditures – $7.5 billion dollars Uniform Formulary Rule – P&T Committee mandated by Congress DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 4 TRICARE Formulary Basic Core Formulary Uniform Formulary Non Formulary Extended Core Formulary DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 5 TRICARE Pharmacy Benefit – Points of Service FY09 POS Rxs 30-day Rxs* 30-day Rxs (%)* % Dollars Total Dollars MTF 48,101,964 80,252,540 44% 19% $1.43 B Retail 71,414,850 73,753,775 40% 67% $5.06 B Mail 10,454,703 Order 30,148,634 16% 14% $1.05 B *Normalized based on 30-day supply of medications DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 6 The PEC Staff DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 7 Responsibilities of the PEC • Evaluate the clinical and cost effectiveness of drug therapy to support the DoD P&T Committee formulary decision-making process • Implement and maintain the DoD pharmacy benefit • Assess the outcomes of drug therapy to improve patient care and provide a feed-back loop for the DoD P&T Committee DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 8 Process Timeline Implementation TMA Director Decision Drug Class Selection PEC completes Clinical and Economic Analysis Beneficiary Advisory Panel Consult with PORT DoD P&T Meeting DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 9 Drug Class Selection • High expenditures across Military Health System (MHS) – “20/80 Rule”: 20% of the drugs comprise 80% of the expenditures • • • • Market competition within a class Expiration of existing DoD or DoD/VA contracts Impending generic competition Newly approved drug likely to impact existing class DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 10 Drug Class Selection • November 2010 P&T meeting – Januvia and Onglyza • Rationale – – – – – Not previously reviewed Significant cost to the DoD Increased utilization Safety concerns Clinical guidelines JANUVIA JANUMET ONGLYZA DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 11 Process Timeline Implementation TMA Director Decision Drug Class Selection PEC completes Clinical and Economic Analysis Beneficiary Advisory Panel Consult with PORT DoD P&T Meeting DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 12 • Team Approach Clinical Analysis Review Process • Drug Class Review – – – – – – Key Questions Background Efficacy Safety Tolerability Other Factors • Formal Presentation – Utilization and Spend – PEC Recommendations DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 13 Clinical Analysis Evidence Based Medicine • Goal – Use the best quality evidence when determining differences within the drug class Meta-analyses and Systematic Reviews Randomized Controlled Trials Non-randomized Trials Cohort and Case Control Studies Poster Presentations Reps 14 Clinical Analysis Evidence Based Medicine • Januvia and Onglyza Evidence – No meta-analysis or systematic reviews – Relied on randomized controlled trials for efficacy and safety – Head-to-Head trial DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 15 Head-to-Head Trial Saxagliptin vs Sitagliptin • • • • 18 week, Phase 3b, MC, DB, non-inferiority trial Saxagliptin 5mg OR Sitagliptin 100mg Stable metformin doses (1500-3000mg/day) Primary endpoint – from baseline A1c – Non-inferiority concluded if upper limit of 2-sided 95% CI of the A1c difference between treatments was <0.3% • Secondary endpoints – % of patients achieving A1c < 6.5% and 7% – from baseline FPG, insulin, C-peptide, proinsulin, HOMA-2 DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 16 •Diabetes Metab Res Rev 2010;26;540-549. Saxagliptin vs Sitagliptin Results SAXA + Met N = 334 SITA + Met N = 343 Mean (SE) A1c at baseline (%) 7.68 (0.052) 7.69 (0.047) Mean (SE) A1c at week 18 (%) 7.16 (0.052) 7.07 (0.051) Adjusted change from baseline A1c (%) Mean (SE) Two-sided 95% CI -0.52 (0.039) -0.60, -0.45 -0.62 (0.038) -0.69, -0.54 Difference in adjusted change from baseline A1c vs sitagliptin + met (%) Mean (SE) Two-sided 95% CI 0.09 (0.055) -0.01, 0.20 - SE = standard error DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 17 •Diabetes Metab Res Rev 2010;26;540-549. Clinical Analysis Provider Input • Developed by the clinical evaluation team • Sent via email using web survey tool • Questionnaire – Physicians – Pharmacists – Other healthcare providers • Summarized responses presented to the P&T Committee • Missing input from civilian network providers • Januvia and Onglyza: Email Invites > 500, Responses 443 DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 18 •Survey: Non-Insulin Anti-Diabetic Agents: To what extent do you agree or disagree with this statement: "In order to treat the majority of y ... DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 19 Economic Analysis Relative Cost-Effectiveness • Two broad types of economic analyses – Pharmacoeconomic Analysis • Evaluates the outcomes and costs of interventions designed to improve health • 4 types – Budget Impact Analysis (BIA) • Accounts for costs associated with a decision • Estimates the likely impact (use and cost) of a formulary decision over 2-3 years DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 20 Types of Pharmacoeconomic Analysis • Cost-Minimization Analysis (CMA) – Treatments are equally effective – Cost is only factor • Cost-Effectiveness Analysis (CEA) – Outcomes vary but can be expressed in a common unit – Combines clinical benefits with cost efficiency • Cost-Utility Analysis (CUA) – Costs and consequences of different interventions in terms of the patient’s health-related quality of life and survival time • Cost-Benefit Analysis (CBA) – Compares the net costs of a health care intervention with the benefits as a result of applying that intervention DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 21 CMA Results $3.00 Retail $2.50 Retail Retail Cost ($)/Day Retail $2.00 $2.00 $1.75 $1.50 MTF MTF $1.00 $1.00 $0.50 MTF MTF Weighted average cost for all 3 POS standardized to drug A market share (46% MTF; 30% RET; 24% MAIL) $0.00 Drug B Drug B Drug B (1 of 1 UF) (1 of 2 UF) (1 of 2 UF/BCF) Drug A DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil $1.55 22 Economic Analysis Decision Criteria Cost NO Rejection threshold Increase Worse MAYBE Better Acceptance threshold Effect MAYBE DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil Decrease YES 23 Process Timeline Implementation TMA Director Decision Drug Class Selection PEC completes Clinical and Economic Analysis Beneficiary Advisory Panel Consult with PORT DoD P&T Meeting DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 24 Pharmacy Outcomes Research Team (PORT) • Co-located in DC and San Antonio – – – – 3 pharmacists 2 pharmacoeconomists Data analyst Technical writer • Improve the outcomes of drug therapy and enhance the quality of the TRICARE pharmacy benefit • Support the DoD P&T Committee and assess the effects of formulary changes on DoD beneficiaries DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 25 “First-line Use”: New Antidiabetic Users No Antidiabetic Rxs Prior 12 Months, Combos w/ Parent Agents •X12 Jul 09 – Jun 10 New users Jul10 Estimated new users/year Total unique utilizers/yr Jul09-Jun10 No antidiab etic Rx 495 5940 93,661 6 98 1176 23,053 5 460 5520 140,156 4 Insulin (any) 1177 14,124 159,665 9 SU 1449 17,388 222,537 8 Metformin 5959 71,508 423,224 17 July 10 DPP-4 GLP-1 TZD % new users •New metformin users represent 17% of all metformin users Other antidiabetics 60 720 16,513 4 •Note: This method counts individuals who received an Rx for a given drug or drug class during a given month (e.g., Jul10) but NOT during the previous 12-month period (e.g., Jul 09 to Jun10); all POS DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 26 “First-Line” Use of DPP-4s • 93,661 unique users Jul 09 – Jun 10 • Estimated new users per year (n) – No antidiabetics at all, last 12 months = 5940 – No DPP-4 last 12 months = 35,364 – No DPP-4, had Met or SU, last 12 months = 27,636 • ~22% of new DPP-4 users had no Met or SU last 12 months • Of these, about 1/3 (1788) had antidiabetics other than Met or SU prior to DPP-4s • So, the percent of new DPP-4 users with no prior antidiabetic use is ~17% DoD/TMA Pharmacoeconomic •DoD Pharmacy Outcomes Center www.pec.ha.osd.mil Research Team 27 Process Timeline Implementation TMA Director Decision Drug Class Selection PEC completes Clinical and Economic Analysis Beneficiary Advisory Panel Consult with PORT DoD P&T Meeting DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 28 DoD P&T Meeting • • • • • • Uniform Formulary placement Basic Core Formulary (BCF) additions Medical necessity criteria for NF drugs Prior authorization requirements Quantity limits Minutes of each meeting include recommendation summaries and supporting documentation DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 29 DPP-4 Inhibitors Relative Clinical Effectiveness • DoD P&T Committee Recommendation on the Relative Clinical Effectiveness (vote) – Motion: The DoD P&T Committee agrees with the relative clinical effectiveness analysis of DPP-4s as presented DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 30 BCF Decision PEC Recommendation • Recommendation – Januvia and Janumet BCF • Justification – Budget impact analysis showed more cost effective when placed on the BCF – Questionnaire results showed preference for a BCF agent DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil •BCF=Basic Core Formulary 31 Medical Necessity vs Prior Authorization • Medical Necessity – Requirement when drugs are made Non-formulary – Five criteria to meet medical necessity • CI, ADR’s, Tx failure, stable patient and unacceptable risk if change to UF drug, no UF alternative – Retail/Mail Order: Fulfilling MN reduces co-pay from $22 (NF) to $9 (UF) – MTF: Fulfilling MN allows pt to receive NF drug at MTF • Prior Authorization – Drug with PA can be in a UF-reviewed class (PDE-5s, biologics for RA), or class not previously reviewed – Assist with ensuring appropriate use •NF=Non-formulary DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil •MTF=Military Treatment Facility •UF=Uniform Formulary 32 Step Therapy • Automated Prior Authorization = Step Therapy – Applies to Retail Network/Mail Order, where computer can look back at patient’s profile – Requires use of preferred agent first, then can try others in the class that are UF – PPIs , BPH drugs, Insomnia • Manual Prior Authorization – When automated PA fails – Physician initiates a call or fills out form DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 33 Step Therapy Automated review of patient profile. Has the patient previously received the preferred product? Prescription written Pharmacy processes prescription PDTS checks patient profile Rx pays YES and is dispensed NO Rx does not pay Prior Authorization required Or, Patient must try the preferred product 34 Process Timeline Implementation TMA Director Decision Drug Class Selection PEC completes Clinical and Economic Analysis Beneficiary Advisory Panel Consult with PORT DoD P&T Meeting DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 35 The Beneficiary Advisory Panel (BAP) Washington DC • Congress established • Focus on implementation of UF decisions – Enhance transparency to beneficiaries • Members – – – – – Active duty family members Retirees and their family members 2 clinical experts outside of the DoD Pharmacist from the US Family Health Plan Physicians or pharmacists from the TRICARE regional contractors DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 36 The BAP • Concerns regarding Januvia and Onglyza – Does the Committee consider the mechanism of action when deciding where to place an agent? – Does a patient need to go through step therapy to use metformin in combination? – Can a patient get Janumet without trying a sulfonylurea or metformin first? DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 37 Process Timeline Implementation TMA Director Decision Drug Class Selection PEC completes Clinical and Economic Analysis Beneficiary Advisory Panel Consult with PORT DoD P&T Meeting DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 38 TRICARE Management Activity (TMA) Director Decision • Dr. Jonathan Woodson • Assistant Secretary of Defense for Health Affairs • Director, TMA DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil • Reviews comments and approves the P&T minutes • After the minutes are approved, the decisions may be made public 39 TRICARE Management Activity (TMA) Signed Minutes DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 40 Process Timeline Implementation TMA Director Decision Drug Class Selection PEC completes Clinical and Economic Analysis Beneficiary Advisory Panel Consult with PORT DoD P&T Meeting DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 41 Implementation • 30, 60, 90, up to 180 day implementation – Based on level of effort and awareness necessary to make the change • Several things happen – – – – – Education Operations Prior Authorization edits-testing Formulary search tool and Epocrates Monitoring • DPP-4 Inhibitors - 60 day implementation DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 42 Summary • Review of the TRICARE formulary is important to help manage a $7.5 billion dollar pharmacy benefit • Formulary management is accomplished through a thorough evaluation of efficacy, safety, and cost • The PEC staff assists the DoD P&T Committee with recommendations that provide the greatest value to the Military Health System DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 43 Questions DoD/TMA Pharmacoeconomic Center www.pec.ha.osd.mil 44 A Peek at the PEC: An Overview of Formulary Management at the TRICARE Management Activity (TMA) Pharmacoeconomic Center (PEC) LCDR Marisol Martinez, PharmD Email: marisol.martinez@amedd.army.mil DoD/TMA Pharmacoeconomic Center Promoting high quality, cost effective drug therapy throughout the Military Health System www.pec.ha.osd.mil